Impact of commonly used drugs on the composition and metabolic function of the gut microbiota

WANG Xuan, Year1 MPhil student

Supervisor: Prof. Christopher K.C. LAI


24 Nov 2023

Outline

- 01 Background and introduction to gut microbiota
- Role of gut microbiota in diseases
- 03 Commonly used drugs influencing gut microbiota
- 04 Conclusion

-Background -

Introduction to gut microbiota



Gut microbiota:

- refers to the complex community of microorganisms that reside in the gastrointestinal tract, particularly the colon (large intestine)
- 10 times more abundant than somatic cells and germ line cells of our body
- Microbiome is 150 times bigger than human genome
- "a metabolic organ"


Diseases associated with the changes in the gut microbiota:


- Obesity
- Diabetes
- Liver diseases
- Neurodegenerative diseases

Role of gut microbiota in diseases

Gut microbiota metabolizes the diet ingested by the host into a series of metabolites:

- short chain fatty acids
- secondary bile acids
- branched-chain amino acids
- Trimethylamine-N-oxide
-






Role of gut microbiota in diseases


Intrinsic and extrinsic factors influencing gut microbiota


Only a minority of gut microbes are shared across the majority of individuals

- In a European data set of 3000 samples, only 17 bacteria were identified as a core microbiome present in >95% of all samples.
- Of the 639 species identified in a population study of 1135 Dutch individuals, 469 (73%) were present in fewer than 10 individuals.




1. Antibiotics






- **Donor A** mice demonstrated an **increase** in *Prevotella* sequences from **D0** (mean 27.4% (SD 5.9%)) to **D8** (mean 44.9% (SD 3.7%)) with a significant **reduction** in this genus by late recovery (mean 13.9% (SD 7.7%))
- There is an **increase** in *Faecalibacterium* at these time points (**D0**—mean 13.1% (SD 10.5%), **D8**—mean 21.3% (SD 5%), **D11** (day 11)—mean 23.6% (SD 13%), **D18** (day 18)—mean 38.5% (SD 7.4%);
- **Bacteroides** decreased throughout the study in the donor B group, although this did not reach significance at any time point (D0—49.3% (SD 17.5%), D8—40.9% (SD 9.7%), D11—31.9% (SD 12%), D18—32.2% (SD 4%))
- Parabacteroides remained largely stable throughout the study.

1. Antibiotics






Red: Donor A Blue: Donor B White: overlap

 More significantly differentially expressed genes were detected in donor A There was an overlap in the genes that were both differentially expressed by A and B

1. Antibiotics

 Gene ontology (GO) analysis reveals marked covariance between the microbiota and GO pathways in donor A mice but not in donor B mice

 Inter-individual variation in the gut microbiota induced by antibiotic may contribute to personalized host responses following microbiota perturbation



2. Proton pump inhibitors (PPI)

Proton Pump Inhibitor Drugs



Commonly used PPIs:

- Pantoprazole
- Omeprazole
- Esomeprazole
-

Indications of PPIs:

- Peptic ulcers
- Gastro-esophageal reflux
- Dyspepsia
- Gastroduodenal disorders and bleeding caused by NSAIDs

Being associated with an increased risk of enteric infections (C. difficile, Salmonella spp, Shigella spp, Campylobacter spp)

2. Proton pump inhibitors

3 independent cohorts comprising 1815 fecal samples

16S rRNA gene analysis




the gut microbiome of PPI users

- Cohort 1: general population
- Cohort 2: patients with IBD
- Cohort 3: IBS case-control cohort

some increased bacteria in PPI users are typically found in the oral microbiome

- Rothia dentocariosa
- Rothia mucilaginosa
- The genera *Scardovia* and *Actinomyces*
- the family Micrococcaceae



Cohort 2

Dataset

Cohort 3 Meta-Analysis

P < 5e-02

P > 5e-02

P > 5e-02

P < 5e-02

Class Mollicutes ily Anaeroplasmataceae

Order Actinomycetale Family Actinomycetaceae

Order [Bifidobacteriales/Actinomycetales]

Order RF39 Class Actinobacteria

2. Proton pump inhibitors

Gut microbiome of PPI users shifts towards the oral microbiome in the first coordinate






Figure. 1. Principal coordinate analysis of 1815 gut microbiome samples and 116 oral microbiome samples



infections

3. Metformin

Gut microbial shifts under metformin treatment



- CHN: Chinese cohort
- MHD: cohort from MetaHIT project in Denmark
- SWE: Swedish cohort


Indirect metformin treatment effects


- reduced intestinal lipid absorption
- lipopolysaccharide (LPS)-triggered local inflammation

The increase of E.coli may contribute to side effects such as diarrhea

3. Metformin

Gut microbial shifts under metformin treatment







- Metformin-untreated patients
- Metformin-treated patients

The level of serum metformin is positively correlated with the abundance of *E. coli*, and in negative correlation with the abundance of *Intestinibacter*

3. Metformin

Metformin-altered microbiota improves glucose tolerance






M0: before metformin treatment


M4: 4 months after metformin treatment


4. Laxatives

Mild and transient diarrhea induced by laxatives leads to long-term changes in the

gut microbiome of mice







4. Other commonly used non-antibiotic drugs

Other commonly used non-antibiotic drugs:

- Statins
- Opioids
- Antidepressants
-

Factors should be taken into account:

- Intestinal transit time
- Stool consistency
- Bacterial quantities (e.g. microbial load per sample)
-

Conclusion

Studying commonly used drugs' impact on gut microbiota will:

- Better understand bi-directional interactions between drugs and microbiota
- Help explain part of the drug's therapeutic function, as well as some of its side effects
- Emphasize the need to rigorously control for confounders like drug use when performing microbiome studies looking at specific diseases or conditions



- Reference

Adak A, Khan MR. An insight into gut microbiota and its functionalities. Cell Mol Life Sci. 2019 Feb;76(3):473-493.

Cani PD. Human gut microbiome: hopes, threats and promises. Gut. 2018 Sep;67(9):1716-1725.

Lindell AE, Zimmermann-Kogadeeva M, Patil KR. Multimodal interactions of drugs, natural compounds and pollutants with the gut microbiota. Nat Rev Microbiol. 2022 Jul;20(7):431-443.

Lavelle A, Hoffmann TW, Pham HP, Langella P, Guédon E, Sokol H. Baseline microbiota composition modulates antibiotic-mediated effects on the gut microbiota and host. Microbiome. 2019 Aug 2;7(1):111.

Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC, Harmsen HJ, Dijkstra G, Franke L, Xavier RJ, Jonkers D, Wijmenga C, Weersma RK, Zhernakova A. Proton pump inhibitors affect the gut microbiome. Gut. 2016 May;65(5):740-8.

Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Pedersen HK, Arumugam M, Kristiansen K, Voigt AY, Vestergaard H, Hercog R, Costea PI, Kultima JR, Li J, Jørgensen T, Levenez F, Dore J; MetaHIT consortium; Nielsen HB, Brunak S, Raes J, Hansen T, Wang J, Ehrlich SD, Bork P, Pedersen O. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015 Dec 10;528(7581):262-266.

- Reference

Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M, Xifra G, Mercader JM, Torrents D, Burcelin R, Ricart W, Perkins R, Fernàndez-Real JM, Bäckhed F. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017 Jul;23(7):850-858.

Tropini C, Moss EL, Merrill BD, Ng KM, Higginbottom SK, Casavant EP, Gonzalez CG, Fremin B, Bouley DM, Elias JE, Bhatt AS, Huang KC, Sonnenburg JL. Transient Osmotic Perturbation Causes Long-Term Alteration to the Gut Microbiota. Cell. 2018 Jun 14;173(7):1742-1754.e17.